LeafNLP Demos
Back to explore

Report #2870594

Received Nov 4, 2025

Reports are unverified and do not show that a vaccine caused an event. Full disclaimer

Overview

Sex
Female
Age
76 yrs
State
IA
Recovered
Unknown
Vaccinated
Oct 21, 2025
Onset
Oct 21, 2025
Days to onset
0
Hospital days
—

Vaccines (1)

TypeNameManufacturerDoseLotRoute / Site
RSVRSV (AREXVY)GLAXOSMITHKLINE BIOLOGICALS2G347X—

Symptoms (1)

Extra dose administered

Symptom narrative

Second dose; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of extra dose administered in a elderly female patient who received RSVPreF3 adjuvanted (Arexvy) (batch number G347X, expiry date 12-DEC-2026) for prophylaxis. Previously administered products included Arexvy (Received 1st dose of Shingrix vaccine in SEP-2024). On 21-OCT-2025, the patient received the 2nd dose of Arexvy. On 21-OCT-2025, an unknown time after receiving Arexvy, the patient experienced extra dose administered (Verbatim: Second dose). The outcome of the extra dose administered was not applicable. Additional Information: GSK Receipt Date: 21-OCT-2025 A patient got a second shot of Arexvy on 21-OCT-2025. First dose was administered back in September 2024. The reporter knew that is a onetime thing, but was curious about adverse effects.